TALLYHO/JngJ response to rosiglitazone

JAX® In Vivo Pharmacology Services examined the ability of the reference compound, rosiglitazone, to lower blood glucose and improve glucose tolerance. TALLYHO/JngJ males at 9 weeks of age (n = 8) were dosed orally with 0, 3, or 30 mg/kg/day for 4 weeks. Fed blood glucose levels were recorded weekly and an oral glucose tolerance test (OGTT) was performed at study termination.

Figure 1. Rosiglitazone at 3mg/kg had no effect, but 30mg/kg progressively lowered fed blood glucose.



Figure 2. Rosiglitazone at 30 mg/kg also improved the ability of TALLYHO/JngJ mice to clear blood glucose following challenge in the OGTT, indicating improved glucose tolerance.